Brokerages expect Hologic, Inc. (NASDAQ:HOLX) to announce $779.91 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Hologic’s earnings, with estimates ranging from $777.70 million to $783.70 million. Hologic posted sales of $715.40 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 9%. The company is expected to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that Hologic will report full-year sales of $779.91 million for the current fiscal year, with estimates ranging from $3.23 billion to $3.28 billion. For the next fiscal year, analysts expect that the company will report sales of $3.40 billion per share, with estimates ranging from $3.37 billion to $3.43 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Hologic.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same quarter last year, the company posted $0.52 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year.
Several equities analysts have commented on HOLX shares. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target for the company in a research report on Wednesday, December 20th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target (up previously from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a research report on Thursday, January 4th. Piper Jaffray Companies reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Hologic presently has a consensus rating of “Buy” and a consensus target price of $48.00.
In other news, Director Namal Nawana acquired 6,600 shares of Hologic stock in a transaction dated Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the acquisition, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Grove Bank & Trust raised its stake in Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares in the last quarter. Hall Laurie J Trustee raised its stake in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Hologic during the 2nd quarter worth $191,000. NuWave Investment Management LLC acquired a new stake in Hologic during the 4th quarter worth $199,000. Finally, National Asset Management Inc. acquired a new stake in Hologic during the 2nd quarter worth $203,000. Institutional investors and hedge funds own 93.84% of the company’s stock.
Shares of Hologic (NASDAQ:HOLX) traded up $0.11 during mid-day trading on Friday, reaching $39.29. 3,099,745 shares of the company’s stock traded hands, compared to its average volume of 3,080,000. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98. Hologic has a 52 week low of $35.33 and a 52 week high of $46.80. The stock has a market cap of $10,860.00, a PE ratio of 15.00, a PEG ratio of 1.77 and a beta of 0.77.
COPYRIGHT VIOLATION WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/18/779-91-million-in-sales-expected-for-hologic-inc-holx-this-quarter.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.